{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:43:18Z","timestamp":1790462598917,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.jmii.2020.03.034","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T02:01:27Z","timestamp":1585965687000},"page":"436-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":396,"title":["Treatment options for COVID-19: The reality and challenges"],"prefix":"10.1016","volume":"53","author":[{"given":"Shio-Shin","family":"Jean","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-Ing","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2020.03.034_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2020.03.034_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s15010-020-01401-y","article-title":"2019 Novel coronavirus: where we are and what we know","author":"Cheng","year":"2020","journal-title":"Infection"},{"key":"10.1016\/j.jmii.2020.03.034_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention","author":"Wu","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2020.03.034_bib4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2020.02.011","article-title":"Are children less susceptible to COVID-19?","author":"Lee","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2020.03.034_bib6","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jmii.2020.02.009","article-title":"2019 Novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China","volume":"53","author":"Huang","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2020.03.034_bib7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.15585\/mmwr.mm6909e1","article-title":"Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020","volume":"69","author":"Burke","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jmii.2020.03.034_bib8","article-title":"Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage","author":"Liu","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.jmii.2020.03.034_bib9","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jfma.2020.02.009","article-title":"SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics","volume":"119","author":"Cao","year":"2020","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jmii.2020.03.034_bib10","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","article-title":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study","volume":"361","author":"Peiris","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2020.03.034_bib11","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2020.03.034_bib12","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1073\/pnas.0409465102","article-title":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry","volume":"102","author":"Hofmann","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jmii.2020.03.034_bib13","article-title":"Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients","author":"Lee","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2020.03.034_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jmii.2020.02.001","article-title":"Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV","volume":"53","author":"Lee","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2020.03.034_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30196-1","article-title":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study","author":"To","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2020.03.034_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jmii.2020.03.034_bib17","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) Is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.jmii.2020.03.034_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jmii.2020.03.034_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jmii.2020.03.034_bib21","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib23","doi-asserted-by":"crossref","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.jmii.2020.03.034_bib24","doi-asserted-by":"crossref","first-page":"105933","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections","author":"Ko","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2020.03.034_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1922083117","article-title":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection","author":"de Wit","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jmii.2020.03.034_bib26","article-title":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection","author":"Wang","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2020.03.034_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.jmii.2020.03.034_bib28","author":"XinhuaNet"},{"key":"10.1016\/j.jmii.2020.03.034_bib29","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jmii.2020.03.034_bib30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jmii.2020.03.034_bib31","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jmii.2020.03.034_bib32","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","author":"Cao","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib33","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMe2005477","article-title":"COVID-19 - the search for effective therapy","author":"Baden","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib34","author":"News"},{"key":"10.1016\/j.jmii.2020.03.034_bib35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/nm.3362","article-title":"Treatment with interferon-\u03b12b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques","volume":"19","author":"Falzarano","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib36","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jmii.2020.03.034_bib37","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/cr.2012.165","article-title":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model","volume":"23","author":"Yan","year":"2013","journal-title":"Cell Res"},{"key":"10.1016\/j.jmii.2020.03.034_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol J"},{"key":"10.1016\/j.jmii.2020.03.034_bib39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.jmii.2020.03.034_bib40","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","author":"Cortegiani","year":"2020","journal-title":"J Crit Care"},{"key":"10.1016\/j.jmii.2020.03.034_bib41","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In\u00a0vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jmii.2020.03.034_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2020.03.034_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.jmii.2020.03.034_bib44","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1001\/jama.2015.13896","article-title":"Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial","volume":"314","author":"Bacharier","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2020.03.034_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.11.003","article-title":"Teicoplanin inhibits Ebola pseudovirus infection in cell culture","volume":"125","author":"Wang","year":"2016","journal-title":"Antivir Res"},{"key":"10.1016\/j.jmii.2020.03.034_bib46","doi-asserted-by":"crossref","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","article-title":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)","volume":"291","author":"Zhou","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jmii.2020.03.034_bib47","doi-asserted-by":"crossref","first-page":"105944","DOI":"10.1016\/j.ijantimicag.2020.105944","article-title":"Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?","author":"Baron","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jmii.2020.03.034_bib48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.antiviral.2019.04.006","article-title":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference","volume":"167","author":"Beigel","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.jmii.2020.03.034_bib49","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S1473-3099(18)30002-1","article-title":"Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study","volume":"18","author":"Beigel","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2020.03.034_bib50","doi-asserted-by":"crossref","first-page":"16226","DOI":"10.1038\/nmicrobiol.2016.226","article-title":"A mouse model for MERS coronavirus-induced acute respiratory distress syndrome","volume":"2","author":"Cockrell","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jmii.2020.03.034_bib51","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1128\/JVI.02232-10","article-title":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response","volume":"85","author":"Glowacka","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2020.03.034_bib52","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.1128\/JVI.00094-12","article-title":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry","volume":"86","author":"Kawase","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.jmii.2020.03.034_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.jmii.2020.03.034_bib54","author":"News"},{"key":"10.1016\/j.jmii.2020.03.034_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30141-9","article-title":"Convalescent plasma as a potential therapy for COVID-19","author":"Chen","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jmii.2020.03.034_bib56","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jmii.2020.03.034_bib57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13054-020-2818-6","article-title":"Treatment of COVID-19: old tricks for new challenges","volume":"24","author":"Cunningham","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.jmii.2020.03.034_bib58","doi-asserted-by":"crossref","DOI":"10.1007\/s11655-020-3192-6","article-title":"Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs","author":"Luo","year":"2020","journal-title":"Chin J Integr Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib59","unstructured":"Lai CC, Wang CY, Hsueh PR.Co-infection among patients with COVID-19.(manuscript submitted)."},{"key":"10.1016\/j.jmii.2020.03.034_bib60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jmii.2018.11.004","article-title":"Recommendations and guidelines for the treatment of pneumonia in Taiwan","volume":"52","author":"Chou","year":"2019","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jmii.2020.03.034_bib61","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/jcm9010275","article-title":"Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia","volume":"9","author":"Jean","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib63","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib66","doi-asserted-by":"crossref","first-page":"m1086","DOI":"10.1136\/bmj.m1086","article-title":"COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists","volume":"368","author":"Day","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jmii.2020.03.034_bib67","author":"Society of Critical Care Medicine"},{"key":"10.1016\/j.jmii.2020.03.034_bib68","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib69","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jmii.2020.03.034_bib70","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1097\/PCC.0b013e3182a55735","article-title":"Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome","volume":"14","author":"W\u00f6sten-van Asperen","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.21037\/atm.2016.11.03","article-title":"Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola","volume":"4","author":"Fedson","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jmii.2020.03.034_bib72","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00398-20","article-title":"Hiding in plain sight: an approach to treating patients with severe COVID-19 infection","volume":"11","author":"Fedson","year":"2020","journal-title":"mBio"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118220300943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118220300943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:24:33Z","timestamp":1761657873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118220300943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1684118220300943"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2020.03.034","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment options for COVID-19: The reality and challenges","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2020.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}